We are live on ! Find out more
VRTX icon

Vertex Pharmaceuticals
VRTX

376 hedge funds and large institutions have $17.1B invested in Vertex Pharmaceuticals in 2013 Q2 according to their latest regulatory filings, with 376 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

46% more call options, than puts

Call options by funds: $419M | Put options by funds: $287M

Holders
376
Holders Change
+376
Holders Change %
–
% of All Funds
12.27%
Holding in Top 10
7
Holding in Top 10 Change
+7
Holding in Top 10 Change %
% of All Funds
0.23%
New
376
Increased
–
Reduced
–
Closed
–
Calls
$419M
Puts
$287M
Net Calls
+$131M
Net Calls Change
+$131M

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
TCIM
26
TIAA CREF Investment Management
New York
$158M +$146M +1,981,252 New
Wells Fargo
27
Wells Fargo
California
$152M +$140M +1,903,231 New
MAA
28
Managed Account Advisors
New Jersey
$149M +$137M +1,864,204 New
BB
29
BB Biotech
Switzerland
$112M +$103M +1,404,445 New
BG
30
BlackRock Group
United Kingdom
$111M +$102M +1,384,112 New
Franklin Resources
31
Franklin Resources
California
$104M +$95.8M +1,300,975 New
FAM
32
Fred Alger Management
New York
$91.6M +$84.2M +1,143,923 New
AAMU
33
Amundi Asset Management US
Massachusetts
$88.5M +$81.6M +1,107,960 New
Deutsche Bank
34
Deutsche Bank
Germany
$86.3M +$79.3M +1,077,425 New
UBS AM
35
UBS AM
Illinois
$77.8M +$71.7M +973,489 New
Geode Capital Management
36
Geode Capital Management
Massachusetts
$72.4M +$66.8M +906,430 New
HCM
37
Holland Capital Management
Illinois
$70.1M +$64.4M +875,150 New
Legal & General Group
38
Legal & General Group
United Kingdom
$69.6M +$64.2M +871,839 New
Norges Bank
39
Norges Bank
Norway
$69.3M +$63.9M +867,345 New
BA
40
BlackRock Advisors
Delaware
$65.1M +$59.9M +813,001 New
TAM
41
Tiverton Asset Management
Delaware
$64M +$58.9M +800,000 New
HM
42
HealthCor Management
New York
$62M +$57.1M +775,000 New
Artisan Partners
43
Artisan Partners
Wisconsin
$60.7M +$55.9M +759,400 New
VOYA Investment Management
44
VOYA Investment Management
Georgia
$59M +$54.4M +738,458 New
New York State Common Retirement Fund
45
New York State Common Retirement Fund
New York
$56M +$51.6M +700,525 New
Barclays
46
Barclays
United Kingdom
$50.1M +$46.1M +625,798 New
CS
47
Credit Suisse
Switzerland
$47.5M +$43.7M +592,838 New
Sumitomo Mitsui Trust Group
48
Sumitomo Mitsui Trust Group
Japan
$46.6M +$42.8M +581,525 New
BIM
49
BlackRock Investment Management
Delaware
$45.2M +$41.5M +563,981 New
SCA
50
SAC Capital Advisors
Connecticut
$44.1M +$40.6M +551,926 New
1
2
3 4 5

VRTX Hedge Fund Activity: Q2 2013 in Review

376 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q2 2013, worth a combined $17.1B.

Buyers outnumbered sellers: 376 funds opened new VRTX positions and 0 closed out — a net gain of 376 holders — while 0 added to existing stakes and 0 trimmed.

  • 376 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $17.1B of Vertex Pharmaceuticals stock for Q2 2013.
  • 376 funds opened new Vertex Pharmaceuticals positions in Q2 2013 and 0 closed out, a net change of +376 holders.

Based on aggregated 13F filings for Q2 2013.